TECFIDERA
Drug
Biogen, Inc.
Total Payments
$34.7M
Transactions
61,677
Doctors
4,503
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $210,140 | 91 | 65 |
| 2023 | $288,392 | 83 | 39 |
| 2022 | $417,025 | 106 | 36 |
| 2021 | $4.7M | 132 | 28 |
| 2020 | $4.0M | 2,252 | 1,112 |
| 2019 | $8.4M | 9,515 | 2,292 |
| 2018 | $7.5M | 20,959 | 2,564 |
| 2017 | $9.2M | 28,539 | 2,773 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.7M | 20,691 | 62.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9.3M | 3,275 | 26.9% |
| Consulting Fee | $2.0M | 406 | 5.8% |
| Travel and Lodging | $964,775 | 4,006 | 2.8% |
| Food and Beverage | $699,527 | 32,046 | 2.0% |
| Education | $12,603 | 1,253 | 0.0% |
Payments by Type
Research
$21.7M
20,691 transactions
General
$13.0M
40,986 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multi-center, randomized, double-blinded assessment of Tecfidera in extending the time to a first attack in radiologically isolated syndrome (RIS) | Biogen, Inc. | $7.5M | 0 |
| Dimethyl Fumarate (DMF) Observational Study | Biogen, Inc. | $6.6M | 2 |
| BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | Biogen, Inc. | $1.8M | 1 |
| Compliant request to open new PO for the Tecfidera 109MS001 Radiologically Isolated Syndrome (RIS) Study in the amount of $12,944,095.25 (20 sites, 210 patients). The UTSW Medical Center/Dr. Darin Okuda will be the Sponsor of this study. | Biogen, Inc. | $1.3M | 0 |
| Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). | Biogen, Inc. | $430,419 | 1 |
| In-vivo investigation of the modulation of retinal atrophy by oral disease modifying therapies in multiple sclerosis: a prospective study | Biogen, Inc. | $316,239 | 0 |
| A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) | Biogen, Inc. | $303,712 | 0 |
| Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | Biogen, Inc. | $294,483 | 0 |
| Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) | Biogen, Inc. | $293,783 | 0 |
| Efficacy of Tecfidera in resolving chronic inflammatory activity in established MS lesions. | Biogen, Inc. | $240,897 | 0 |
| Restoring glutathione synthesis with Tecfidera: An in vivo H-MRS single-arm study at 7T in patients with relapsing-remitting multiple sclerosis | Biogen, Inc. | $199,796 | 0 |
| Cleveland Clinic - BPF Analysis for DEFINE | Biogen, Inc. | $196,679 | 0 |
| Role of the fumarates-NRF2 pathway in the reparative molecular and cellular phenotypes of human cerebral organoids after injury | Biogen, Inc. | $174,874 | 0 |
| Retrospective Evaluation of De-Escalation from antiCD-20 Therapies to Fumarates | Biogen, Inc. | $172,609 | 0 |
| Brain atrophy in DMF-treated vs untreated RRMS patients: retrospective real world data | Biogen, Inc. | $142,073 | 0 |
| US-BGT-17-11251 (PI Smoot): Dr. Enrique Alvarez (Colorado) - Tec GI management early vs recent (AOP18-343) | Biogen, Inc. | $142,062 | 0 |
| A Multicenter Global Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) | Biogen, Inc. | $142,047 | 0 |
| 2016: MGH, Sponsored research agreement for 2 research studies to support Tecfidera | Biogen, Inc. | $125,372 | 0 |
| INFLUENCE OF TECFIDERA TREATMENT OF MULTIPLE SCLEROSIS ON IMMUNE CELL SUBSETS AND GENE EXPRESSION | Biogen, Inc. | $112,272 | 0 |
| Determine whether Tecfidera modulates the peripheral immune milieu | Biogen, Inc. | $102,980 | 0 |
Top Doctors Receiving Payments for TECFIDERA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Buffalo, NY | $61,099 | 43 |
| Sunita Tummala | Neurology | Flint, MI | $61,074 | 71 |
| , MD | Neurology | Pittsburgh, PA | $60,879 | 53 |
| , D.O | Neurology | Phoenix, AZ | $60,696 | 138 |
| , MD | Neurology | Patchogue, NY | $60,345 | 65 |
| Barry Singer | Neurology | Saint Louis, MO | $60,304 | 53 |
| , MD | Neurology | Pittsburgh, PA | $60,263 | 38 |
| , MD | Neurology | Buffalo, NY | $59,741 | 55 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Savannah, GA | $59,039 | 71 |
| , M.D | Neurology | San Antonio, TX | $58,220 | 51 |
| , MD | Neurology | Macon, GA | $57,349 | 62 |
| , M.D | Neurology | Hampton, VA | $56,915 | 109 |
| , M.D | Neurology | Fredericksburg, VA | $56,734 | 56 |
| , MD | Neurology | Bellevue, OH | $56,307 | 45 |
| , MD | Neurology | Thousand Oaks, CA | $55,883 | 116 |
| , M.D | Neurology | Los Angeles, CA | $55,341 | 65 |
| Peter Wade | — | Hartford, CT | $54,934 | 77 |
| , MD | Neurology | Saint Clair Shores, MI | $54,188 | 68 |
| , MD | Neurology | Englewood, CO | $53,476 | 71 |
| , MD PHD | Neurology | Albany, NY | $53,475 | 44 |
| , M.D | Neurology | Portland, OR | $52,145 | 86 |
| , M.D | Neurology | Tampa, FL | $52,080 | 95 |
| , DO | Vascular Neurology | Ocala, FL | $51,766 | 101 |
| , DO | Neurology | Hinsdale, IL | $51,523 | 71 |
| , D.O | Neurology | Owosso, MI | $50,906 | 48 |
Ad
Manufacturing Companies
- Biogen, Inc. $34.7M
Product Information
- Type Drug
- Total Payments $34.7M
- Total Doctors 4,503
- Transactions 61,677
About TECFIDERA
TECFIDERA is a drug associated with $34.7M in payments to 4,503 healthcare providers, recorded across 61,677 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2017 to 2024. In 2024, $210,140 was paid across 91 transactions to 65 doctors.
The most common payment nature for TECFIDERA is "Unspecified" ($21.7M, 62.4% of total).
TECFIDERA is associated with 20 research studies, including "Multi-center, randomized, double-blinded assessment of Tecfidera in extending the time to a first attack in radiologically isolated syndrome (RIS)" ($7.5M).